News & Event
- Home
- News
- News & Event
Chungbuk-do to establish the gene and cell therapy manufacturing infrastructure by investing KRW 8 bn
On July 29, Chungbuk-do announced that it will actively push forward with the "Gene and Cell Therapy Innovation Manufacturing Infrastructure Project" to secure competitiveness in the field of gene and cell therapy, which is emerging as a core component of the next-generation advanced biotechnology industry.
Gene and cell therapy has recently been recognized as the only hope for personalized precision medicine and the treatment of rare and incurable diseases.
The global market is expected to grow at an average annual rate of over 20%, from USD 6 billion in 2020 to USD 46.5 billion by 2030.
However, challenges remain in terms of the lack of prototype production infrastructure and high costs, making it difficult for private companies to establish facilities, conduct research and development (R&D), and commercialize products.
To address these issues, the province plans to spend KRW 8 billion over two years, as part of the infrastructure development project within the "Advanced Regenerative Bio Global Innovation Zone" designated last year. The goal is to establish key facilities for gene therapy production by the end of next year.
These facilities, to be located at the Ochang branch of the Korea Research Institute of Bioscience and Biotechnology, will be quipped with virus vector production facilities, gene and cell therapy production process facilities, and automated cell culture and purification equipment.
An official from Chungbuk-do stated, "We will do our best to promote this project in cooperation with the government, research institutions, and companies, so that Chungbuk-do can become a prominent center for advanced biotechnology."
jeonch@yna.co.kr
Source Text
** This article was translated from Korean.
Date
2025.08.01
Views
85
According to Yonhap News,
On July 29, Chungbuk-do announced that it will actively push forward with the "Gene and Cell Therapy Innovation Manufacturing Infrastructure Project" to secure competitiveness in the field of gene and cell therapy, which is emerging as a core component of the next-generation advanced biotechnology industry.
Gene and cell therapy has recently been recognized as the only hope for personalized precision medicine and the treatment of rare and incurable diseases.
The global market is expected to grow at an average annual rate of over 20%, from USD 6 billion in 2020 to USD 46.5 billion by 2030.
However, challenges remain in terms of the lack of prototype production infrastructure and high costs, making it difficult for private companies to establish facilities, conduct research and development (R&D), and commercialize products.
To address these issues, the province plans to spend KRW 8 billion over two years, as part of the infrastructure development project within the "Advanced Regenerative Bio Global Innovation Zone" designated last year. The goal is to establish key facilities for gene therapy production by the end of next year.
These facilities, to be located at the Ochang branch of the Korea Research Institute of Bioscience and Biotechnology, will be quipped with virus vector production facilities, gene and cell therapy production process facilities, and automated cell culture and purification equipment.
An official from Chungbuk-do stated, "We will do our best to promote this project in cooperation with the government, research institutions, and companies, so that Chungbuk-do can become a prominent center for advanced biotechnology."
jeonch@yna.co.kr
Source Text
Copyrights Yonhap News. All Rights Reserved.
Reprint or redistribution without permission is prohibited.
Source: Yonhap News (July 29, 2025)
** This article was translated from Korean.